E-drug: Prices of antimalarial combinations
-------------------------------------------------------------------------
Dear E-Druggers,
Zambia is at the edge of changing the drug of first choice for
treatment of malaria due to increased resistance to chloroquine.
There are recommendations to use Sulphadoxine + Pyramethamine
as the first drug of choice for non serious malaria. The second
choice would be Amodiaquine. Quinine shall remain the drug of
choice for severe malaria. There is also an interest to explore further
the new combination drugs and artemether derivatives. For
example, Pyramethamine + Dapsone, Chlorproguanil + dapsone,
Artemether + Benflumetol and any other candidates on the horizon.
Do you have information on any of the following questions:
- What are the current prices per tablet based on international bulk
procurement?
- What are best-guess projections on prices for the next several
years?
With regard to current and projected production capacity (cost
aside):
- How soon could we expect these drugs to be available in
sufficient volume for producers to bid on tenders for 10's of
millions of treatment courses?
Thanks,
Oliver Hazemba
Regional Technical Advisor
Rational Pharmaceutical Management Plus
Centre for Pharmaceutical Management
Management Sciences for Health
Red Cross Building
2837 Los Angeles Blvd. Long Acres
Lusaka, ZAMBIA
Phone: +260-1-254555/3/2
e-mail: ohazemba@zamnet.zm
--
Send mail for the `E-Drug' conference to `e-drug@usa.healthnet.org'.
Information and archive http://satellife.healthnet.org/programs/edrug.html
Mail administrative requests to `majordomo@usa.healthnet.org'.
For additional assistance, send mail to: `owner-e-drug@usa.healthnet.org'.